INT351096

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 1.35
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (FKBP1A, MTOR) cytosol (FKBP1A, MTOR) signal transduction (FKBP1A, MTOR)
isomerase activity (FKBP1A) mitochondrion (MTOR) Golgi apparatus (MTOR)
FKBP1A (Homo sapiens)
MTOR (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 6 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Carcinoma 12 96.96 Very High Very High Very High
Renal Cell Carcinoma 87 95.80 Very High Very High Very High
Death 6 70.84 Quite High
Metastasis 21 61.08 Quite High
Cancer 60 54.84 Quite High
Renal Cancer 6 17.80 Low Low
Pneumonia 48 5.00 Very Low Very Low Very Low
Disease 39 5.00 Very Low Very Low Very Low
Toxicity 30 5.00 Very Low Very Low Very Low
Stomatitis 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Everolimus (Afinitor®; RAD001; Novartis, USA) is an orally bioavailable mTOR inhibitor that binds with high affinity to its intracellular receptor FKBP12, at the same point in the mTOR pathway as temosirolimus.
FKBP12 Binding (binds) of mTOR
1) Confidence 0.28 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.49 Pain Relevance 0
The everolimus-FKBP12 complex binds to mTOR and reduces the activity of the downstream effectors S6 ribosomal protein kinase (S6K1) and translational repressor protein eukaryotic elongation factor 4E-binding protein (4EBP).19 eIF-4F activation results in the translation of a subset of capped mRNA containing highly structured 5?
FKBP12 Binding (binds) of mTOR
2) Confidence 0.27 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.36 Pain Relevance 0
Everolimus (Afinitor®; RAD001; Novartis, USA) is an orally bioavailable mTOR inhibitor that binds with high affinity to its intracellular receptor FKBP12, at the same point in the mTOR pathway as temosirolimus.
FKBP12 Binding (binds) of mTOR
3) Confidence 0.27 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox